Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021092196 - ANTI-TIGIT ANTIBODIES AND USES THEREOF

Publication Number WO/2021/092196
Publication Date 14.05.2021
International Application No. PCT/US2020/059139
International Filing Date 05.11.2020
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applicants
  • MERCK PATENT GMBH [DE]/[DE]
  • ZHANG, Dong [CN]/[US] (US)
  • KELTON, Christie [US]/[US] (US)
  • LI, Liwei [US]/[US] (US)
  • NANNEMANN, David [US]/[US] (US)
Inventors
  • ZHANG, Dong
  • KELTON, Christie
  • LI, Liwei
  • NANNEMANN, David
Agents
  • BISHOP, Kathryn
Priority Data
62/930,65105.11.2019US
63/048,35106.07.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-TIGIT ANTIBODIES AND USES THEREOF
(FR) ANTICORPS ANTI-TIGIT ET LEURS UTILISATIONS
Abstract
(EN)
The present application relates to anti-TIGIT antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of infectious diseases and cancer.
(FR)
La présente invention concerne des anticorps anti-TIGIT ou des fragments de liaison à l'antigène de ceux-ci, un acide nucléique codant pour ceux-ci, des compositions thérapeutiques de ceux-ci, et leur utilisation pour améliorer la fonction des lymphocytes T pour réguler à la hausse les réponses immunitaires à médiation cellulaire et pour traiter des troubles dysfonctionnels des lymphocytes T, tels que l'immunité tumorale, pour le traitement de maladies infectieuses et du cancer.
Latest bibliographic data on file with the International Bureau